Dear Sir, An A to G transition mutation at nucleotide 3243 of the tRNALeU 0VR of the mitochondrial DNA (rot DNA), was recently reported in NIDDM patients characterized by maternal inheritance and associated deafness (MIDD) [1] [2] , with an estimated prevalence of 1-2 % [3 and unpublished results]. The same mutation is also found in the clinically different MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) [4] [5] . MIDD and MELAS present in cells, including lymphocytes, mutant mitochondrial D N A and wild type DNA. However, heteroplasmy levels vary according to the tissue and to the individual carrying the same defect. Classic screening for such a mutation is based on an isotopic polymerase chain reaction (PCR) of the region, followed by a specific digestion. The mutation creates an ApaI restriction site which is never found in control subjects. However, this technique suffers from low sensitivity (particularly when the rate of heteroplasmy in blood cells is low) and consequently requires at least a week of autoradiography to distinguish positive from negative results.
Therefore, we have established a non-isotopic, quick and sensitive method to detect this mutation in mt D N A using the Pharmacia PhastSystem. PCR was performed on a Perkin Elmer 600 thermal cycler (Perkin Elmer, Branchburg, USA) using 200 ng genomic DNA, extracted from lymphocytes, 0.2 mmol/l dNTR 50 ng of each primers A and B (A: CAC TTG TTC C T r A A A TAG GG and B: A G C G A A GGG TTG TAG TAG CC) and 1 unit Ta polymerase (Perkin Elmer). Cycling conditions were: a first denaturation at 94 ~ for 5 minthen 30 cycles of 30 s at 94 ~ 56 ~ and 72 ~ and a final extension at 72 ~ for 6 rain. PCR products of 850 bp were digested for 2 h at 25 ~ with the restriction enzyme ApaI (Biolabs, Beverly, USA). After a pre-run of the non-denaturing pre-cast polyacrylamide gels (12.5%) (Pharmacia, Uppsala, Sweden) at 200 Vh, samples were automatically loaded and run at 4 ~ for 100 Vh. Gels were then transferred in the coloration unit on the PhastSystem, silver stained and dried. A gel with eight different DNAs is presented (Fig. 1) , five of them carrying the mutation. The presence of the A -> G mutation in patient's D N A is detected by two additional bands of 630 and220 bp after the ApaI digestion (lanes indicated by M), as compared to wild type mt D N A for which a unique band of 850 bp is detected (lanes indicated by N) .
The use of the PhastSystem enabled a very sensitive and reproducible detection of this mutation and avoided the use of radioelements. Moreover, with this system, we were able to detect the presence of a mutation in 2 h.
Using this technique, we screened NIDDM patients and families referred to us by clinicians, for the presence of the mutation. Patients were either affected by diabetes associated with deafness or they belonged to a family where the mutation had been detected previously. We identified the mutation in 24 NIDDM patients from seven different families.
In conclusion, this test should be very helpful to improve diagnosis of patients affected with maternally-inherited diabetes associated with deafness. The same assay can also be used to recognize individuals carrying this mutation and who are at risk of developing either MIDD or the MELAS syndrome. 
